[HTML][HTML] Lutathera® Orphans: State of the Art and Future Application of Radioligand Therapy with 177Lu-DOTATATE
Lutathera® is the first EMA-and FDA-approved radiopharmaceutical for radioligand therapy
(RLT). Currently, on the legacy of the NETTER1 trial, only adult patients with progressive …
(RLT). Currently, on the legacy of the NETTER1 trial, only adult patients with progressive …
[HTML][HTML] VIPoma: Mechanisms, clinical presentation, diagnosis and treatment
L Abdullayeva - World Academy of Sciences Journal, 2019 - spandidos-publications.com
Vasoactive intestinal peptide (VIP) secreting tumour (VIPoma) is a rare neuroendocrine
tumour that most often originates from pancreatic islet cells and affects one in ten million …
tumour that most often originates from pancreatic islet cells and affects one in ten million …
[PDF][PDF] Skin involvement in neuroendocrine neoplasia
Neuroendocrine neoplasia (NEN), priory known as neuroendocrine tumours represent the
modern approach of traditionally named “carcinoid” tumours. We shortly introduce benign …
modern approach of traditionally named “carcinoid” tumours. We shortly introduce benign …